PGC-1α调控糖尿病肾脏病的作用机制及中医药干预的研究进展

Research progress on the regulatory mechanism of PGC-1α in diabetic kidney disease and the intervention of traditional Chinese medicine

关键词:  PGC-1α  糖尿病肾脏病  中医药  作用机制  研究进展

Key words:  PGC-1α  diabetic kidney disease  traditional Chinese medicine  mechanism of action  research progress

摘要:

糖尿病肾脏病（DKD）是糖尿病最常见和最严重的微血管并发症之一，发病机制复杂，目前治疗手段难以有效阻止其进展且多有局限性。近年来，研究发现过氧化物酶体增殖物激活受体（PPAR）γ共激活因子-1α（PGC-1α）在调节血糖和线粒体自噬、抗氧化应激、炎症反应、细胞凋亡和改善肾脏纤维化等方面发挥重要作用，与DKD的进展密切相关。而中医药可通过调节PGC-1α的表达，多靶点、多通路延缓DKD的进展。因此，文章通过梳理PGC-1α在DKD中的作用机制，系统总结了中药靶向PGC-1α干预DKD的研究进展，旨在为DKD的治疗提供新的思路。

Abstract:

Diabetic kidney disease（DKD）is one of the most common and severe microvascular complications of diabetes，with a complex pathogenesis. Current treatment methods are difficult to effectively halt its progression and often have limitations. In recent years，research has found that peroxisome proliferator-activated receptor（PPAR）γ coactivator-1α（PGC-1α）plays a significant role in regulating blood glucose，mitophagy，oxidative stress，inflammatory responses，apoptosis，and improving renal fibrosis，all closely related to the progression of DKD. Traditional Chinese medicine can delay the progression of DKD by regulating the expression of PGC-1α through multiple targets and pathways. Therefore，this article systematically reviews the mechanisms of PGC-1α in DKD and summarizes the research progress on traditional Chinese medicine targeting PGC-1α to intervene in DKD，aiming to provide new insights for the treatment of DKD.